(Q38069617)

28 August 2017

1 reference

title

The evolving pharmacotherapy of pulmonary fibrosis (English)

1 reference

28 August 2017

0 references

1 reference

Harpreet K Lota

1

1 reference

28 August 2017

Athol U Wells

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 January 2013

1 reference

Expert Opinion on Pharmacotherapy

28 August 2017

published in

1 reference

28 August 2017

volume

14

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

79-89

1 reference

Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Role of endothelin in fibrosis and anti-fibrotic potential of bosentan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

High-dose acetylcysteine in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Small-molecule inhibitors of NADPH oxidase 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Pirfenidone in idiopathic pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Pirfenidone in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Anticoagulant therapy for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Interstitial lung disease in systemic sclerosis: a simple staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Cyclophosphamide versus placebo in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Fibrotic disease and the T(H)1/T(H)2 paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Rituximab treatment of the anti-synthetase syndrome: a retrospective case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Pulmonary Sarcoidosis: A Prospective Evaluation of Glucocorticoid Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Outcome of the treatment for sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.758250

10.1517/14656566.2013.758250

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference